Severe intellectual disability, omphalocele, hypospadia and high blood pressure associated to a deletion at 2q22.1q22.3: case report

Milene Vianna Mulatinho1, Cassio Luiz de Carvalho Serao2, Fernanda Scalco3, David Hardekopf4, Sona Pekova4, Kristin Mrasek5, Thomas Liehr5, Anja Weise5, Nagesh Rao6 and Juan Clinton Llerena Jr1*

Abstract

Background: Recently, array-comparative genomic hybridization (aCGH) platforms have significantly improved the resolution of chromosomal analysis allowing the identification of genomic copy number gains and losses smaller than 5 Mb. Here we report on a young man with unexplained severe mental retardation, autism spectrum disorder, congenital malformations comprising hypospadia and omphalocele, and episodes of high blood pressure. An ~ 6 Mb interstitial deletion that includes the causative genes is identified by oligonucleotide-based aCGH.

Results: Our index case exhibited a de novo chromosomal abnormality at 2q22 [del(2)(q22.1q22.3)dn] which was not visible at the 550 haploid band level. The deleted region includes eight genes: HNMT, SPOPL, NXPH2, LOC64702, LRP1B, KYNU, ARHGAP15 and GTDC1.

Discussion: aCGH revealed an ~ 6 Mb deletion in 2q22.1 to 2q22.3 in an as-yet unique clinical case associated with intellectual disability, congenital malformations and autism spectrum disorder. Interestingly, the deletion is co-localized with a fragile site (FRA2K), which could be involved in the formation of this chromosomal aberration. Further studies are needed to determine if deletions of 2q22.1 to 2q22.3 define a new microdeletion syndrome.

Keywords: Array-comparative genomic hybridization (aCGH), Fluorescence in situ hybridization (FISH), 2q22 deletion syndrome, Birth defects, Hypospadia, omphalocele, Severe mental retardation, Essential hypertension, High blood pressure

Introduction

Intellectual disability (ID) or Mental Retardation (MR) affects a large number of individuals, and was recently estimated to have a prevalence of 1% in the general population [1]. Chromosomal abnormalities are causative factors in 4% to 34.1% of cases, detected mainly by G-band-based banding studies [2,3]. The advent of array-comparative genomic hybridization (aCGH) has increased the detection rate by an additional 15–20% [4], generally by identifying submicroscopic chromosomal abnormalities. This progress has enabled a refined association of chromosomal aberrations and potentially underlying disease-causing genes, leading to better karyotype/genotype-phenotype correlations, and more qualified genetic counseling for families [5-8].

Genes associated with ID/MR can be found distributed throughout the human genome. According to the OMIM database [9] six genetic syndromes have been assigned to chromosomal region 2q22 to 2q23, including, Mowat-Wilson Syndrome (MWS) (MIM:235730); Nemaline Myopathy 2 (MIM:256030); Meier-Gorlin Syndrome 2 (MIM:613800); Susceptibility to Asthma (MIM:600807); Idiopathic Generalized Epilepsy 9 (MIM:607682); and, Hypogonadism, Alopecia, Diabetes Mellitus, Mental Retardation and Extrapyramidal Signs syndrome (MIM:241080). MWS is the best known disease in 2q22 ~ q23, presenting multiple congenital anomalies including Hirschsprung disease (HD) (MIM:142623) and MR. It has been recently
associated with truncating mutations and/or heterozygous deletions of the ZEB2 homeobox gene (ZFHX1B) [10-13]. Here we present a Brazilian patient carrying a hitherto unreported ~6 Mb microdeletion in 2q22.1 to 2q22.3 upstream and outside the ZEB2 region [14]. The patient’s phenotype comprises severe autism spectrum disorder, associated to ID/MR, and congenital malformations, such as, omphalocele and hypospadias with cryptorchidism. Episodes of essential hypertension were an important feature in adolescence and were controlled with specific anti-hypertensive agents.

Case presentation
The patient is the only son of a young non-consanguineous couple, without any familial history. He was born at term by cesarean section; weight 3.950 g (>P50th percentile); length 51 cm (50th percentile). The patient had his first genetic evaluation at 4 years of age, being referred due to global developmental delay, lack of speech, an omphalocele (corrected by surgery), and balanic hypospadias with bilateral cryptorchidism. At physical examination he presented a coarse face with deep-set eyes, thick eyebrows, protruding tongue, small teeth, pointed chin, bulbous nose, wide spaced and hypoplastic nipples, scoliosis, corrected balanic hypospadias with a flattened gland, bilateral clinodactyly of the fifth finger, non-specific dermatoglyphic pattern, global developmental delay and behavioral disorder. A neurological evaluation through the Childhood Autism Rating Scale (CARS) protocol revealed a score of 44.5, compatible with an autism spectrum disorder.

Clinical follow-up proceeded on different occasions, and a series of hypertension episodes were detected when the patient was 17 years old, ranging from 150x100 mm Hg to 140x80 mm Hg. His body mass index (BMI) was 40 kg/m², without any echocardiogram or electrocardiogram disturbance. Complete blood count, cranial cerebral tomography, thyroid hormones and biochemical evaluation were all normal, except for high triglycerides (289 mg/dl [normal values: 50–200 mg/dl]). He was treated with an angiotensin-converting enzyme inhibitor (captopril 25 mg daily) and dietetic measures, losing more than 40 kg in 2 years.

Recently, a new clinical evaluation was performed. He is currently 23 years old and presents in good physical health, with a BMI of 27.5 kg/m² and normalization of his blood pressure without the use of antihypertensive drugs. He still suffers from a severe behavioral disorder, occasional tantrums, stereotyped movements of his trunk and repetitive whistling. Such clinical signs have improved dramatically with the use of antipsychotic drugs. Differential diagnoses such as Smith-Magenis, Simpson-Golabi-Behmel and Beckwith-Wiedemann syndromes have been ruled.

Results
In the current case, G-banding and subtelomeric screening as well as molecular testing for the FMR1 and FMR2 genes were all normal (data not shown). aCGH identified an interstitial deletion of 6 Mb in the long arm of chromosome from 2q22.1 to 2q22.3, spanning positions 138,750,000 to 144,750,000 (Figure 1) and comprising eight genes (Table 1) [14]. The molecular cytogenetic karyotype according to ISCN 2009 was designated as: arr 2q22.1q22.3(138,750,000–144,750,000)x1. Seven out of 10 FISH probes used in the 2q22.1 band confirmed the deletion (Table 2). Eight to fourteen metaphase spreads were evaluated (Figure 2). The absence of xanthurenic acid in the patient’s urine showed that the metabolic pathway of tryptophan was not altered.

Discussion
A 23-year-old patient with ID/MR, autism, essential hypertension, and congenital malformations including

![Figure 1 NimbleGen whole-genome oligonucleotide aCGH profile for chromosome 2q](image-url)
an omphalocele and hypospadias with cryptorchidism is reported. He carries an ~6 Mb de novo microdeletion at 2q22.1–22.3 identified by an oligonucleotide aCGH panel [arr 2q22.1q22.3(138,750,000–144,750,000)x1 dn] according to Human Genome Assembly Build 37 (hg19).

Table 3 summarizes the clinical and genomic data from our index case and four patients described in the Decipher database with overlapping deletion intervals (138,750,000 to 144,750,000 bp) [17]. ID/MR is a common clinical feature, but none of the other listed cases presented with congenital malformations such as those found in our patient. Besides ID/MR, two patients show other common clinical features: strabismus and thick eyebrows (Patient 2566); and strabismus, bulbous nasal tip, and hypoplastic/inverted/absent nipples (Patient 1607). Interestingly, Patient 1607 has a complex karyotype involving chromosomes 2, 3 and 5 [18]. None of the individuals listed in Table 3 shared the exact breakpoints at 2q22.1–q22.3 as observed in our patient [17].

A child with MWS presenting with delayed psychomotor development, hypotonia, a variety of dysmorphic features, genitourinary anomalies and a severe course of HD has been described with a deletion at 2q22.2 to 2q22.3 [143,468,147–147,106,860] [19]. This 3.6 Mb aberration included ZEB2 and three other genes not currently associated with disease—KYNU, ARHGAP15 and GTDC1—all encoding for proteins involved in ubiquitous and non-specific pathways [20–22]. This deletion segment overlaps with our case in an ~1.2 Mb [143,468,147–144,750,000] comprising KYNU, ARHGAP15 and GTDC1 (Table 1). The authors speculate that those genes could play a crucial role in the process of tissue regeneration [19]. While many candidate genes have been studied to investigate their role in birth defects such as omphalocele and hypospadias/cryptorchidism [23–25], the clinical observations in our patient suggests the assignment of such malformations to the genes in the region 2q22.2–2q22.3.

Particularly interesting seems to be the function of the gene KYNU. It has previously been mentioned as possibly participating in a three-gene interaction influencing hypospadia, cryptorchidism and/or omphalocele [19].

| Table 1 Genes within the 2q22.1 to 2q22.3 deleted region according to OMIM [9] |
|----------------------------------|-------------|---------------------------------|---------------------|
| gene symbol | name | OMIM # | description | function |
| HNMT | NM_006895 | 605238 | Homo sapiens histamine N-methyltransferase (HNMT), transcript variant 1. | It metabolizes Histamine in mammals. This gene encodes the first enzyme, which is found in the cytosol and uses S-adenosyl-L-methionine as the methyl donor. This variant (1) represents the longest transcript and it encodes the longest protein (isoform 1). |
| SPOPL | NM_001001664 | Homo sapiens speckle-type POZ protein-like (SPOPL), mRNA | - |
| NXPH2 | NM_007226 | 604635 | Homo sapiens neurexophilin 2 (NXPH2), mRNA. | - |
| LOC647012 | NR_033658 | Homo sapiens YY1 transcription factor pseudogene (LOC647012), non-coding RNA. | - |
| LRP1B | NM_018557 | 608766 | LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 1B | LRP1B belongs to the low density lipoprotein (LDL) receptor gene family. These receptors play a wide variety of roles in normal cell function and development due to their interactions with multiple ligands. |
| KYNU | NM_001052998; NM_003937 | 605197 | Homo sapiens kynureninase (KYNU) | Kynureninase is a pyridoxal-5′-phosphate (pyridoxal-P) dependent enzyme that catalyzes the cleavage of L-kynurenine and L-3-hydroxykynurenine into anthranilic and 3-hydroxyanthranilic acids, respectively. Kynureninase is involved in the biosynthesis of NAD cofactors from tryptophan through the kynurenine pathway. Alternative splicing results in multiple transcript variants. |
| ARHGAP15 | NM_018460 | 610578 | Homo sapiens Rho GTPase activating protein 15 (ARHGAP15), mRNA | RHO GTPases (see ARHA; MIM 165390) regulate diverse biologic processes, and their activity is regulated by RHO GTPase-activating proteins (GAPs), such as ARHGAP15. |
| GTDC1 | NM_018460; NM_024659; NM_001006636 | 61065 | Homo sapiens glycosyltransferase-like domain containing 1 (GTDC1) | GTDC1 is ubiquitously expressed at relatively high levels in lung, spleen, testis, and peripheral blood leukocytes, suggesting that it may have biochemical functions in these organs. |
However, a polymorphism in KYNU has also been linked to essential hypertension in a group of Han Chinese [26]. This feature has been investigated by studies that show the influence of KYNU as a candidate for hypertension in spontaneously hypertensive rats [27,28]. KYNU encodes kynureninase, a vitamin B6-dependent enzyme involved in the kynurenine pathway for the biosynthesis of NAD cofactors from tryptophan, and its deficiency has been associated with abnormal tryptophan metabolism (MIM:605197) [22]. A massive urinary excretion of xanturenic acid known as hydroxykynurenuria or xanturenic aciduria (MIM:236800) can be detected in cases of kynureninase deficiency, due to defects in the kynurenine pathway [22,29]. Based on the literature, an investigation was done to detect the presence of xanthurenic acid in our patient's urine to examine the function of this gene. This biochemical study showed a normal level of xanthurenic acid, indicating that the tryptophan pathway is not affected and with a likely normal gene function. This result is in accordance with the low rank of 91.4% in the Decipher database, indicating that this gene is more likely to not exhibit haploinsufficiency [17]. Finally, genes and/or susceptibility loci on the long arm of chromosome 2 have been recently linked to blood pressure and hypertension by genome-wide association studies, such as STK39 at 2q24.3 [30]; PMS1 and MSTN, both at 2q32.2 [31]; DS2S2382 and DS2S338 at 2q35–q37 [32].

Within the region 2q22.1–2q22.3, no functions have yet been assigned to SPOPL, NXPH2 or LOC647012. HNMT is the only gene currently associated with human disease (Asthma) [9]. Our patient, however, has not shown any episodes of asthma. Special attention should be given to LRP1B, which is a newly identified member of the LDL receptor family. It was originally described as a putative tumor suppressor in lung cancer cells, but its expression profile in several regions of the adult human brain such as cortex, hippocampus and cerebellum suggests it may have additional functions in the central nervous system [33-35]. Its interaction with the β-amyloid

| Locus | signals | BACs | Accession number | Start position (bp) | End position (bp) |
|-------|---------|------|-----------------|-------------------|------------------|
| 2q22.1 | 2x | RP11-112 N16 | AC010873 | 137,567,308 | 137,747,509 |
| 2q22.1 | del | RP11-731 F1 | AC069394.6 | 138,791,256 | 138,964,607 |
| 2q22.1 | del | RP11-59P14 | AC097523 | 138,954,985 | 139,129,617 |
| 2q22.1 | del | RP11-251E19 | AC0926202 | 139,299,060 | 139,450,096 |
| 2q22.1 | del | RP11-137 J9 | AC092837 | 139,462,901 | 139,629,396 |
| 2q22.1 | del | RP11-432O12 | AC023468 | 139,608,867 | 139,779,382 |
| 2q22.1 | del | RP11-15D9 | AC109345 | 139,736,474 | 139,903,043 |
| 2q22.1 | del | RP11-164E7 | AC108036 | 141,266,879 | 141,423,790 |
| 2q22.3 | 2x | RP11-64O2 | AQ237761 AQ237759 | 145,181,324 | 145,355,222 |
| 2q23.3 | 2x | RP11-58 K7 | AQ201454 AQ201457 | 153,385,449 | 153,743,069 |

Figure 2 Three pairs of chromosome 2 are shown to illustrate the FISH results obtained with the BAC probes. a) RP11–587 K7 in 2q23.3 (green) and RP11–112 N16 in 2q22.1 (red) were located outside the deleted region. b) RP11–64O2 in 2q22.3 (green) is located outside the deleted region, while RP11–731 F1 in 2q22.1 (red) is within the affected region. c) RP11–137 J9 (green) and RP11–164E7 (red) both are missing on the derivative chromosome 2, indicating deletions in 2q22.1.
precursor protein could protect against the pathogenesis of Alzheimer's disease [33]. Expression of this gene has also been reported in the thyroid and salivary gland [34].

LRP1B is a very large human gene (1.9 Mb), located at 2q22.1 close to the fragile site, FRA2K, at 2q22.3 [36]. Many large genes residing within unstable chromosomal regions are highly evolutionarily conserved, and in general are not traditional mutational targets; however, genomic alterations can occur due to fragile site instability and contribute to diseases, including a variety of cancers [37]. Furthermore, there are important potential linkages between such genomic alterations and neurological development or neurodegeneration, for e.g. CNTNAP2 (2.3 Mb) localized within FRA7I at 7q35 found disrupted in a family with Gilles de la Tourette syndrome [38], and PARK2 (1.3 Mb) mutated in autosomal recessive juvenile Parkinson disease and located in the active center of FRA6E at 6q26 [39].

Fragile sites are understood to be specific loci that preferentially exhibit gaps and breaks in metaphase chromosomes following partial inhibition of DNA synthesis, and their break-prone areas are almost equally distributed along chromosomes [36,40]. Human chromosome 2 has the highest number of fragile sites, with twenty one break-prone regions spaced at an average distance of 11.52 Mb [36]. The deletion studied in this report is placed at 2q22.1q22.3, overlapping FRA2K (2q22.3) and preceded by FRA2F at 2q21.3. This is in line with the fact that regions of chromosomal instability at or near fragile sites are hot-spots for deletions and other alterations [41].

The fragile site neighboring 2q22.1q22.3 may have facilitated the chromosomal aberration in our patient including the entire LRP1B gene region. Moreover, a haploinsufficiency rank of 13.8% was recently established for this gene, just above the 0–10% range indicating a high likelihood of exhibiting haploinsufficiency [17]. If LRP1B is haploinsufficient in our patient, and considering its biological function within the central nervous system, it is tempting to speculate on the participation of this gene in the patient's observed cognitive impairment. In addition, the presence of SNP variant rs2890652 (142,676,401) in LRP1B has been associated with BMI by genome wide association analysis [42]. While it is clear that correlation with potentially functional variants does not prove that these variants are causal, they can provide initial clues into which genes might be prioritized in further studies [42]. Consequently, LRP1B should be the subject of further studies to assign its relationship with BMI.

**Conclusion**

Here we describe a patient presenting severe ID/MR, autism spectrum disorder, dysmorphism and congenital malformations, with episodes of high blood pressure.

| Patient | Cytogenetic deletion | sex | Interval start-end (bp, hg19) | Interval (Mb) | RefSeq Gene | Phenotype |
|---------|----------------------|-----|-------------------------------|--------------|-------------|-----------|
| This report | 2q22.1q22.3 | Male | 138,750,000–144,750,000 | 6 | HNMT, SPOPL, NXP2, LOC647012, LRP1B, KYNU, ARHGAP15, GTDC1 | Omphalocele, cryptorchidism, hypospadia. ID/MR, deep-set eyes, strabismus, thick eyebrow, protruding tongue, small teeth, pointed chin, bulbous nose, wide spaced nipples, hypoplastic nipples, bilateral clinodactyly of fifth finger, non-specific dermatoglyphic patterns, scoliosis, global developmental delay and behavioral disorder. Autism spectrum disorder. |
| 1607 | 2q22.1q22.3 | Female | 139,813,180–145,063,389 | 5,25 | HNMT, SPOPL, NXP2, LRP1B, KYNU, ARHGAP15, GTDC1 | ID/MR, strabismus, bulbous nasal tip, hypoplastic/inverted/absent nipples. |
| 2566 | 2q22.1q22.3 | Female | 143,635,233–147,935,002 | 4,30 | LRP1B, KYNU, ARHGAP15, GTDC1 | – |
| 250662 | 2q22.1q22.3 | Male | 141,232,786–147,935,002 | 6,70 | HNMT, SPOPL, NXP2, LRP1B, KYNU, ARHGAP15, GTDC1 | – |
| 251811 | 2q22.1q22.3 | Female | 143,715,235–146,369,069 | 2,65 | LRP1B, KYNU, ARHGAP15, GTDC1 | – |

**LEGEND:** Important data from five individuals with overlapping intervals are shown. The RefSeq genes and the phenotype columns list only the genes and the clinical findings shared with our patient. Full information of gene contents and phenotype from the Decipher patients is seen at Decipher website [17].
associated with high levels of BMI. A whole-genome aCGH screening revealed an approximate 6 Mb de novo deletion, and a review of the literature provides indications of a new contiguous gene syndrome located in 2q22.1 to 2q22.3.

Methods
Peripheral blood chromosome analysis at the 550 G-band level was performed applying standard cytogenetic procedures. Molecular testing for *FMR1* and *FMR2* genes was performed [43,44], and the subtelomeric ToTel Vysion panel of probes (Abbott–Vysis) was also done. DNA from the patient was isolated from lymphocytes according to standard protocols and was subjected to aCGH analysis [Human Whole-Genome CGH; NimbleGen Systems, Madison, WI] to evaluate the presence of pathogenic copy number changes. The platform contained 385,000 oligonucleotides at a median spacing of 6 kb. The data was analyzed with the NimbleGen SignalMap v.1.9 software. Fluorescence in situ hybridization (FISH) using standard protocols with the following BAC clones as probes were used to confirm the deletion: RP11-112 N16, RP11-731 F1, RP11-597P14, RP11-231E19, RP11-137 J9, RP11-432O12, RP11-15D9, RP11-164E7, RP11-64O2, RP11-58 K7 (Table 2) [15,16].

Urinary organic acids were analyzed to evaluate the metabolic pathway of tryptophan once the *KYNU* gene was found to be deleted inside the 2q22 region (Table 1). This biochemical analysis was performed by high-resolution gas chromatography coupled to mass spectrometry (Agilent 5975 C, HP-5).

Consent
Written informed consent was obtained from the parents of the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Acknowledgements
We are thankful for the patient’s family collaboration in this study, to Dr. Marcia Pimentel from SERGEN, UERJ, for her kind help to allow us to use their molecular biology laboratory to perform *FMR1* and *FMR2* analysis. This work was partially supported by Brazilian grants: MVM received scholarships from CAPES (BEX 3692-05-1) and CNPq/PIOCRUZ (170060/2010-1) and JCL Jr was granted by CNPq (Edital 061/2008; # 490754/2008-2). U19AI067697 grant (NR) from UCLA. Supported in part by the BMBF/DLR BRA 09/020.

Author details
1Instituto Fernandes Figueira, IFF/IOCruz, Departamento de Genética Médica, Av. Rui Barbosa, 716. Flamengo, Rio de Janeiro, RJ 22250-020, Brazil.
2Faculdade de Ciências Médicas, Hospital Universitário Pedro Ernesto, Universidade do Estado do Rio de Janeiro, UERJ, Rio de Janeiro, RJ, Brazil.
3Laboratório de Erros Inatos do Metabolismo, Departamento de Bioquímica, Instituto de Química, Universidad Federal do Rio de Janeiro, UFRJ, Rio de Janeiro, RJ, Brazil.
4Chrombin Laboratory for Molecular Diagnostics (member of the Synlab Czech laboratory group), Prague, Czech Republic.
5Jena University Hospital, Friedrich Schiller University, Institute of Human Genetics, Kollegien gasse 10, D-07743 Jena, Germany.
6Department of Pathology and Lab Medicine, The David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

Authors’ contributions
MVM drafted the manuscript, performed the cytogenetic analysis and the FISH subtelomeric screening, the molecular analysis for *FMR1* and *FMR2*, and analyzed and interpreted the aCGH data. CLC5 and JCL Jr carried out clinical examination and evaluation of the patient. FS performed the biochemical analysis. DH and SP isolated and provided the BAC probes. KM performed the BAC-FISH relevant confirmation. AW, TL, NR and JCL Jr coordinated the study. All authors improved and approved the manuscript.

Received: 4 March 2012 Accepted: 11 June 2012
Published: 11 June 2012

References
1. Maulik PK, Mascarénas MN, Mathers CD, Dua T, Saxena S: Prevalence of intellectual disability: a meta-analysis of population-based studies. Res Dev Disabil 2008, 32(2):419–436.
2. Cepe S, Sonmez FM, Karaguzel A: Chromosomal abnormalities in 457 Turkish patients with MCA/MB, Turk J Pediatr 2006, 48(2):130–134.
3. Xu J, Chen Z: Advances in molecular cytogenetics for the evaluation of mental retardation. Am J Med Genet C Semin Med Genet 2003, 117C(1):15–24.
4. Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, Church DM, Crolla JA, Eicher EE, Epstein CJ, Faucett WA, Feuk L, Friedman JM, Hamosh A, Jackson L, Kaminsky EB, Kol K, Kranz ED, Kuhn RM, Lee C, Ostell JM, Rosenberg C, Scherer SW, Spinner NB, Stavropoulos DJ, Tepperberg JH, Thorland EC, Vermeesch JR, Wagggoner DJ, Watson MS, Martin CL, Ledbetter DH: Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 2010, 86:749–764.
5. Mulatinho M, Llerena I, Uren TP, Rao PN, Quinto-Rivera F: Deletion (1)(p32.2-p32.3) detected by array-CGH in a patient with developmental delay/mental retardation, dysmorphic features and low cholesterol: a new microdeletion syndrome? Am J Med Genet A 2008, 146A(12):2984–2990.
6. Slavotinek AM: Novel microdeletion syndromes detected by chromosome microarrays, Hum Genet 2008, 124(1):1–17.
7. Ballif BC, Theisen A, McDonald-McGinn DM, Zackai EH, Hersh JH, Beijani BA, Shaffer LG: Identification of a previously unrecognized microdeletion syndrome of 16q11.2q12.2. Clin Genet 2008, 74(5):469–475.
8. Park SJ, Jung EH, Ryu RS, Kang HW, Ko JM, Kim HJ, Cheon CK, Hwang SH, Kang HY: Clinical implementation of whole-genome array CGH as a first-tier test in 5080 pre and postnatal cases. Mol Cytogenet 2011, 4:122.
9. OMIM. Online Mendelian Inheritance in Man http://www.ncbi.nlm.nih.gov/omim/.
10. Mowat DR, Croaker GD, Cass DT, Kerr BA, Chaitow J, Ades LC, Chia NL, Wilson MJ: Hirschsprung disease, microcephaly, mental retardation, and characteristic facial features: delineation of a new syndrome and identification of a locus at chromosome 2q22-q23. J Med Genet 1998, 35(8):617–623.
11. Amiel J, Lyonnet S: Hirschsprung disease, associated syndromes, and genetics: a review. J Med Genet 2001, 38(11):729–739.
12. Zweier C, Albrecht B, Mullita B, Behrens R, Beece M, Gillessen-Kaesbach G, Rott HD, Rauch A: “Mowat-Wilson” syndrome with and without Hirschsprung disease is a distinct, recognizable multiple congenital
anomalies-mental retardation syndrome caused by mutations in the zinc finger homebox 18 gene. Am J Med Genet 2002, 108(3):177–181.

13. Zweier C, Temple IK, Beemer F, Zacker E, Lerman-Sagie T, Wescbeke B, Anderson CE, Rauch A: Characterization of deletions of the ZFHX1B region and genotype-phenotype analysis in Mowat-Wilson syndrome. J Med Genet 2003, 40(6):601–605.

14. Database of Genomic Variants. Genomic Variants in Human Genome GRCh 37/Feb.2009 (hg 19) http://projects.tcag.ca/cgi-bin/variation/gbrowse/hg19/.

15. UCSC GENOME BIOINFORMATICS genome.ucsc.edu.

16. DECIPHER database decipher.sanger.ac.uk.

17. Hoffman MJ, Hilhorst-Hofstee Y, Knippenburg J, Hansson KB, Engelberts AC, Laan LA, Bakker E, Rosenberg C: A 6 Mb deletion in band 2q22 due to a complex chromosome rearrangement associated with severe psychomotor retardation, microcephaly and distinctive dysmorphic facial features. J Med Genet 2007, 50(2):149–154.

18. Smigiel R, Szafrańska A, Czyżewska M, Rauch A, Zweier C, Patkowski D: Severe clinical course of Hirschsprung disease in a Mowat-Wilson syndrome patient. Acta Paediatr 2010, 101(1):111–113.

19. Seoh ML, Ng CH, Yong J, Lim L, Leung T: ArthGP15, a novel human RacGAP protein with GTPase binding property. FEBS Lett 2003, 539(1–3):131–137.

20. Zhao E, Li Y, Fu X, Zhang JY, Zeng H, Zeng L, Lin Y, Chen J, Yin G, Qian J, Ying K, Xie Y, Zhao RC, Mao YM: Cloning and expression of human GTCD1 gene (glycophosphatidylinositol biosynthesis) from human fetal DNA. DNA Cell Biol 2004, 23(3):183–187.

21. Christensen M, Duno M, Lund AM, Skovby F, Christensen E: Xanthurenic aciduria due to a mutation in KYNU encoding kynureninase. J Inherit Metab Dis 2007, 30(2):248–255.

22. Beleza-Mireles A, Lundberg F, Lagerstedt K, Zhou X, Omrani D, Frisen L, Nordenskold A, FGFR2, FGFR3 and BMP7: candidate genes for hypospadias. Eur J Hum Genet 2007, 15(1):405–409.

23. Grati FR, Turolia L, D’Apolito P, Ruggieri A, Miozzo M, Bracalente G, Baldò D, Laurino L, Boldorini F, Frate E and others: X-linked mental retardation with hypospadias. Eur J Med Genet 2011, 54(1):35–41.

24. Zhang Y, Zhang KX, He X, Yuan WT, Wang GL, Mao SF, Gao PJ, Huang W, Zhu DL: A polymorphism of kynureninase gene in a hypertensive candidate chromosome disorder region is associated with essential hypertension. Zhonghua Xue Xuan Guan Bing Za Zhi 2003, 33(7):588–591.

25. Mizutani K, Sugimoto K, Okuda T, Katsuya T, Miyata T, Tanabe T, Hijaki G, Oghira T, Yamori Y, Tsujita Y, Tago N, Iwai N. Kynureninase is a novel candidate gene for hypertension in spontaneously hypertensive rats. Hypertens Res 2002, 25(1):135–140.

26. Kwock JB, Kapoor R, Gotoda T, Iwamoto Y, Izuka Y, Yamada N, Isaacs KE, Kushwaha WH, Church WB, Schofield PR, Kapoor V: A missense mutation in kynurenine aminotransferase-1 in spontaneously hypertensive rats. J Biol Chem 2002, 277(39):35777–35782.

27. Komnorn GM, Wilson V, Clamp JR, Westall RG: Hydroxykynureninuria: a Case of Abnormal Transpyruvotable Metabolism Probably Due to a Deficiency of Kynureninase. Arch Dis Child 1964, 39:259–266.

28. Wang Y, O’Connell JR, McArdle PF, Wade JB, Dorff SE, Shi X, Pan L, Rampeusser E, Shen H, Kim JD, Subramanya AR, Scott LJ, Timpson NJ, Tyer JP, van Wingenderen S, Watanabe WM, White CC, Wilkink F, Barlassina C, Chiesa DI, Cooper MN, Janssen J, Lawrence RW, Pelikka N, Prokopenko I, Shi J, Thiering E, Aliev H, Ali FB, Arnold MN, Aspelund T, Atwood LD, Balfour B, Balfour AJ, Bennett AJ, Ben-Shlomo Y, Bergman RN, Bergmann S, Biebermann H, Blakemore AI, Boes T, Bowness CL, Boonstra SW, Brown MJ, Buchanan TA, et al: Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet 2010, 42(11):937–948.

29. Haddad LA, Mingrino-Netto RC, Vianna-Morgante AM, Penna SD: A PCR-based test suitable for screening for fragile X syndrome among mentally retarded males. Hum Genet 1996, 97(8):808–812.

30. Santos CB, Costa Lima MA, Pimentel MM: A new PCR assay useful for screening of FRAXE/FRMR2 mental impairment among males. Hum Mutat 2002, 19(2):157–162.

Cite this article as: Mulatinho et al: Severe intellectual disability, hypospadias, hypospadias and high blood pressure associated to a deletion at 2q22.1q23.2: case report. Molecular Cytogenetics 2012 5:30.